Overview:

 About GPP

• Generalised Pustular Psoriasis (GPP), also known as von Zumbusch psoriasis, is a rare, chronic, systemic autoinflammatory form of pustular psoriasis. It can affect the body in various ways but It is characterized byrecurrent flares of widespread sterile pustules with erythematous, painful skin. GPP can be associated with systemic inflammation including fevers and/or hepatic, gastrointestinal, musculoskeletal, renal, or pulmonary involvement. It is potentially life-threatening, if left untreated. It is important to note that GPP is not contagious and cannot be transmitted to others.

GPP has no known cause but,

1. 1. It is believed to have a genetic component, with the IL-36 pathway playing an important role in disease etiology. IL-36RN’s mutation causes production of unregulated cytokines leading to inflammation of skin.
   2. Additional triggers include
      • Stress
      • Certain medications (Analgesics, Anti-hypertensives, Antimicrobials etc.)
      • Hormonal changes (e.g. during pregnancy).

• Studies reflect higher predominance of the disease in women due to hormonal fluctuations during pregnancy and menstruation. One subtype of Generalized pustular psoriasis is pustular psoriasis of pregnancy. It is usually observed more in 40-50-year-old adult demographic, although children can develop it as well (depending on their genetic makeup). Published studies estimates the prevalence to vary from 18–12.4 per 100,000 people worldwide.
• Treatment for GPP in key geographic regions such as, US, EU4, UK etc., primarily rely on the following approaches-

1. General measures
   • Emollients and moisturisers.
   • Intravenous fluids and electrolytes.
   • Analgesia
   • If pregnant, careful monitoring of mother and foetus.
2. Specific measures
   • Topical agents
   • Phototherapy — usually in combination with systemic agents.
   • Antibiotics in the case of secondary bacterial infection.
   • Non-biologic agents
   • Biologic agents

Currently, only SPEVIGO is approved in the United States. In contrast, Japan has a broader therapeutic landscape for Generalized Pustular Psoriasis, including supportive treatment regimens.

• Significant strides are being made in GPP landscape. In May, 2024 Findings from two phase 3 trials of AnaptysBio’s Imsidolimab (an investigational humanized IgG4 antibody) showed positive results in patients with In March, 2024, USFDA gave Spevigo expanded approval based on data from the phase 2 Effisayil-2 study which included patients 12 years of age and older. Spevigo is a humanized monoclonal immunoglobulin G1 antibody developed by Boehringer Ingelheim.

• The drug pipeline for Generalised Pustular Psoriasis (GPP) is dominated by big pharmaceutical players such as AnaptysBio, Takeda, Johnson & Johnson, Inmagene Biopharmaceuticals Ltd, Boehringer Ingelheim International GmbH, AbbVie, Amgen, UCB Biopharma S.P.R.L., etc. These are the major drivers of the clinical research and development for this rare condition.

Scope of the Report-

1. GPP Overview: Comprehensive insight into Generalised Pustular Psoriasis (GPP), covers the following factors-

• • Epidemiology,
  • Prevalence
  • Global distribution, with a focus on demographic variations
  • Key risk factors (stress, certain medications, and hormonal changes) and Genetic predispositions

2. Pathophysiology:

• • Diving into the pathophysiological mechanisms of GPP
  • Highlighting it’s Cutaneous and Non-cutaneous features
  • Recurrent flares of widespread sterile pustules with erythematous.
  • Fevers and/or hepatic, gastrointestinal, musculoskeletal, renal, or pulmonary involvement. 

3. Therapeutic Landscape: Evaluation of current treatment modalities, including-

• • Lifestyle modifications
  • General measures (moisturisers, IV fluids and electrolytes, analgesia, monitoring of mother and foetus)
  • Pharmacotherapy
  • Phototherapy — usually in combination with systemic agents.
  • Insights into emerging treatments such as gene therapy, Biologics, and advanced drug therapies etc.

4. Disease Management: Discussion on comprehensive management strategies

• • Covering multidisciplinary care
  • Patient education
  • Adherence to treatment protocols
  • Disease stabilization
  • Prevention of complications.

5. Research Advances:

• • Review of recent research findings
  • Clinical trials
  • Innovative therapeutic targets
  • Personalized medicine
  • Development of novel pharmacological agents

6. Market Analysis:

• • Analysis of market dynamics
  • Trends
  • Investment opportunities in GPP therapeutics
  • Market size, key players, and regulatory landscape to guide strategic decision-making and investment planning.

7. Healthcare Burden: Assessment of the global healthcare burden and economic implications of GPP, including

• • Cost-effectiveness of different treatments
  • Policy considerations
  • Strategies to enhance access to innovative therapies

Market Landscape Assessment

To maintain competitiveness in the Generalised Pustular Psoriasis (GPP) domain in the short to mid-long term, it is important to understand the complete GPP development pipeline. This involves staying updated on the evolving treatment landscape, upcoming advancements, and competitive strategies.

Figure 1 GPP development pipeline

Company Profiles

Profiles of key stakeholders advancing Generalised Pustular Psoriasis (GPP) solutions offer valuable insights into their financial standing, product portfolios, and recent innovations within the sector.

Figure 2 Company Profile

Patent Analysis:

This report examines patents associated with Generalised Pustular Psoriasis (GPP), highlighting notable innovations and emphasizing opportunities for improvement or collaboration within the field.

Figure 3 Patent Legal status of Standard current assignees

Figure 4 Region-wise patent count of standard current assignees

Market Assessment/Forecast:

This report forecasts upcoming advancements, outlines pathways for expansion, and provides critical insights into market dynamics, including scale, revenue forecasts, and growth opportunities.

Figure 5 Country-wise Forecast

Competitive Landscape:

The competitive landscape section offers a comprehensive analysis of key market players in the Generalised Pustular Psoriasis (GPP) domain, including their market shares and concise profiles detailing strengths, weaknesses, and strategies. Additionally, it provides competitive benchmarking services for comparative performance insights and industry standards.

Figure 6 Scoring of key players in GPP domain

Report Highlights:

1. Advanced Technologies:

Explore cutting-edge and latest diagnostic and treatment solutions to address the complexities of GPP, enabling precise disease management and treatment planning to improve patient outcomes.

2. Therapeutic Breakthroughs:

Investigate emerging therapies targeting specific molecular abnormalities in GPP, revolutionizing treatment paradigms and offering new hope for enhanced quality of life and functional outcomes for patients.

3. Global Insights:

Assess worldwide trends and investment opportunities in GPP management, providing valuable insights into the evolving landscape of disease management, fostering enhanced diagnostic precision, and treatment efficacy on a global scale.

4. Collaborative Initiatives:

Highlighting key partnerships propelling innovation and advancements in GPP management strategies, promoting collaborative efforts aimed at enhancing patient care and improving the quality of life for individuals affected by the disease.

Report Insights:

1. Innovative Diagnostic Technologies:

Explore cutting-edge diagnostic techniques and patented advancements enhancing precision in GPP diagnosis and treatment. These breakthroughs aim to transform patient care and improve management strategies, offering new approaches for early detection and personalized treatment.

2. Market Drivers and Barriers:

Identify growth areas and obstacles in GPP diagnosis, streamlining processes for affected individuals and enhancing healthcare delivery. Recognize opportunities for advancing diagnostic and treatment approaches to address challenges associated with this complex skin disease, optimizing patient outcomes and reducing healthcare burdens.

3. Trends in GPP Market Dynamics:

Stay updated on evolving trends in GPP diagnosis, including advancements in imaging modalities and non-invasive diagnostic tools. These developments shape the diagnostic landscape and expand treatment options for patients, improving early detection and intervention.

4. Advancements in GPP Technology Pipeline:

Evaluate recent breakthroughs broadening treatment options and improving accuracy in GPP diagnosis. From novel drug therapies to minimally invasive procedures, these advancements hold promise for enhancing patient outcomes and quality of life, driving progress in GPP management.

5. Clinical Trials in GPP Technology:

Stay abreast about ongoing clinical trials contributing to enhanced accessibility and precision in therapeutic interventions for GPP. These trials drive therapeutic advancements and improve patient care by evaluating the efficacy and safety of new treatments and technologies.

6. Leadership in GPP Research:

Understand the leading companies and research institutions pioneering innovation in GPP diagnosis and treatment. Their efforts facilitate advancements in managing the complexities of this challenging skin disorder, shaping the future of GPP care through collaborative research and development initiatives.

In order to give the most precise estimations and forecasts, Wissen Research uses an extensive and iterative research approach that is focused on reducing deviation. The company blends top-down and bottom-up methodologies for market segmentation and quantitative estimation. In addition, data triangulation, which examines the market from three separate angles, is a recurrent topic present in all of our research studies. Important components of the approach used for all of our studies include the following:

Preliminary data mining

On a wide scale, unprocessed market data is collected. Continuous data filtering makes sure that only verified and authenticated sources are taken into account. Additionally, data is extracted from a wide range of reports in our repository and from a number of reputable premium databases. We gather information from raw material suppliers, distributors, and purchasers to help with this since understanding the entire value chain is crucial for a thorough understanding of the market.

Surveys, technical symposia, and trade magazines are used to gather information on technical concerns and trends. Technical information focusing on white space and freedom of movement is also obtained from an intellectual property standpoint. Additionally, information on the industry’s drivers, constraints, and pricing patterns is obtained. As a result, a variety of original data are included in the material that is then cross-validated and certified with published sources.

Statistical model

We use simulation models to generate our market projections and estimates. Every study receives a special model that is tailored to it. Data for market dynamics, the technology environment, application development, and pricing patterns are gathered and supplied into the model all at once for analysis. The relative relevance of these factors is investigated, and their impact on the forecast period is assessed, using correlation, regression, and time series analysis. The process of market forecasting combines technological analysis with economic strategies, practical business acumen, and subject expertise.

Econometric models are frequently used for short-term forecasting, but technology market models are typically employed for long-term forecasting. These are based on a confluence of the business environment, regulatory environment, economic projection, and technical landscape. In order to develop global estimates, it is preferable to estimate markets from the bottom up by integrating data from key regional markets. This is required to ensure accuracy and a complete comprehension of the subject. Among the variables taken into account for forecasting are:

• Market drivers and restraints, as well as the current and anticipated effects of each scenario for raw materials and supply versus pricing patterns

Regulations and anticipated developments

• Present capacity and anticipated capacity growth to 2033

We give these criteria weights and use weighted average analysis to assess their market influence in order to calculate the anticipated market growth rate.

Data Collection Matrix:

1. Introduction
1.1. Overview of GPP
1.2. Causes and Risk Factors
1.3. Symptoms and Diagnosis
1.4. Epidemiology, Prevalence and Incidence
2. Treatment Approaches
2.1. Current Treatment Approaches
2.2. Research on New Treatment Options
2.3. Our Report Focus
3. Market Insight
3.1. Market Trends in GPP
3.2. Market Drivers and Challenges
3.3. Recent Developments
3.3.1. Mergers and Acquisitions
3.3.2. Collaborations, Partnerships, and Agreements
3.3.3. Product Launches and Approvals
4. Patent Analysis
4.1. Top Assignees in GPP Technology
4.2. Geography Focus of Top Assignees
4.3. Legal Status of GPP Patents
4.4. Assignee Segmentation
4.5. Network Analysis of Top Collaborating Entities in GPP Patent Applications
4.6. Technology Evolution in GPP
4.7. Key Patents in GPP
4.8. Patent Trends and Innovations
4.9. Key Players and Patent Portfolio Analysis
5. Clinical Trial Analysis
5.1. Overview of GPP Clinical Trials
5.2. Analysis by Trial Registration Year
5.3. Analysis by Phase of Development
5.4. Analysis by Number of Patients Enrolled
5.5. Analysis by Status of Trial
5.6. Analysis by Study Design
5.7. Analysis by Intervention Type
5.8. Analysis by Geography
5.9. Analysis by Key Sponsors/Collaborators
6. Market Forecast (2024-2034)
6.1. Methodology
6.2. Assumptions
6.3. Projected Growth of GPP Market (2024-2034)
6.3.1. Global GPP Market (2024-2034)
6.3.1.1. By Therapy
6.3.1.1.1. Monoclonal Antibodies
6.3.1.1.2. Biologics and Non-biologics
6.3.1.1.3. Phototherapy
6.3.1.1.4. Others
6.3.1.2. By Route of Administration
6.3.1.2.1. Topical
6.3.1.2.2. Intravenous
6.3.1.2.3. Others
6.3.2. Market Value Forecast in North America, Europe, and Asia Pacific (2024-2034)
6.3.2.1. By Therapy
6.3.2.1.1. Monoclonal Antibodies
6.3.2.1.2. Biologics and Non-biologics
6.3.2.1.3. Phototherapy
6.3.2.1.4. Others
6.3.2.2. By Route of Administration
6.3.2.2.1. Topical
6.3.2.2.2. Intravenous
6.3.2.2.3. Others
7. Competitive Landscape
7.1. Benchmarking Parameters
7.2. Scoring of Different Companies
7.3. Top Company Profiles
7.3.1. AnaptysBio
7.3.2. Takeda
7.3.3. Johnson & Johnson
7.3.4. Inmagene Biopharmaceuticals
7.3.5. Boehringer Ingelheim
7.3.6. AbbVie
7.3.7. Amgen
7.3.8. UCB Biopharma
7.3.9. Company 9
7.3.10. Company 10
7.3.11. Others
7.4. Product Portfolio Analysis
7.5. Recent Developments and Strategies
8. Future Outlook and Market Opportunities
8.1. Technological Advancements in GPP Research
8.2. Unmet Needs and Potential Market Gaps
9. Conclusion
10. Appendix
10.1. Glossary of Terms
10.2. List of Abbreviations

LIST OF FIGURES

LIST OF GRAPHS

LIST OF TABLES